Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 1.94
BIO's Cash-to-Debt is ranked lower than
55% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.86 vs. BIO: 1.94 )
Ranked among companies with meaningful Cash-to-Debt only.
BIO' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.06  Med: 0.9 Max: 1.94
Current: 1.94
0.06
1.94
Equity-to-Asset 0.67
BIO's Equity-to-Asset is ranked higher than
66% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. BIO: 0.67 )
Ranked among companies with meaningful Equity-to-Asset only.
BIO' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.33  Med: 0.51 Max: 0.67
Current: 0.67
0.33
0.67
Interest Coverage 2.42
BIO's Interest Coverage is ranked lower than
91% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 77.70 vs. BIO: 2.42 )
Ranked among companies with meaningful Interest Coverage only.
BIO' s Interest Coverage Range Over the Past 10 Years
Min: 2.42  Med: 5.04 Max: 7.69
Current: 2.42
2.42
7.69
Piotroski F-Score: 4
Altman Z-Score: 4.50
Beneish M-Score: -2.77
WACC vs ROIC
8.71%
1.65%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % 2.57
BIO's Operating Margin % is ranked lower than
52% of the 166 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.66 vs. BIO: 2.57 )
Ranked among companies with meaningful Operating Margin % only.
BIO' s Operating Margin % Range Over the Past 10 Years
Min: 2.57  Med: 9.81 Max: 14.74
Current: 2.57
2.57
14.74
Net Margin % 1.36
BIO's Net Margin % is ranked higher than
53% of the 165 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.76 vs. BIO: 1.36 )
Ranked among companies with meaningful Net Margin % only.
BIO' s Net Margin % Range Over the Past 10 Years
Min: 1.36  Med: 5.98 Max: 9.63
Current: 1.36
1.36
9.63
ROE % 1.09
BIO's ROE % is ranked higher than
51% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.21 vs. BIO: 1.09 )
Ranked among companies with meaningful ROE % only.
BIO' s ROE % Range Over the Past 10 Years
Min: 1.09  Med: 8.85 Max: 13.27
Current: 1.09
1.09
13.27
ROA % 0.73
BIO's ROA % is ranked higher than
55% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.30 vs. BIO: 0.73 )
Ranked among companies with meaningful ROA % only.
BIO' s ROA % Range Over the Past 10 Years
Min: 0.73  Med: 4.77 Max: 6.63
Current: 0.73
0.73
6.63
ROC (Joel Greenblatt) % 6.10
BIO's ROC (Joel Greenblatt) % is ranked higher than
53% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.22 vs. BIO: 6.10 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
BIO' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 6.1  Med: 25.09 Max: 36.51
Current: 6.1
6.1
36.51
3-Year Revenue Growth Rate -1.80
BIO's 3-Year Revenue Growth Rate is ranked lower than
65% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.30 vs. BIO: -1.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
BIO' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -1.8  Med: 8.5 Max: 21
Current: -1.8
-1.8
21
3-Year EBITDA Growth Rate -14.40
BIO's 3-Year EBITDA Growth Rate is ranked lower than
74% of the 130 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.40 vs. BIO: -14.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
BIO' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -14.4  Med: 11 Max: 40.2
Current: -14.4
-14.4
40.2
3-Year EPS without NRI Growth Rate -29.30
BIO's 3-Year EPS without NRI Growth Rate is ranked lower than
80% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.20 vs. BIO: -29.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
BIO' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -29.3  Med: 10.7 Max: 76.3
Current: -29.3
-29.3
76.3
GuruFocus has detected 5 Warning Signs with Bio-Rad Laboratories Inc $BIO.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» BIO's 10-Y Financials

Financials (Next Earnings Date: 2017-05-23 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

BIO Guru Trades in Q1 2016

Jim Simons 144,900 sh (+77.79%)
Steven Cohen Sold Out
Private Capital Sold Out
John Rogers 1,004,492 sh (-0.14%)
Mario Gabelli 66,500 sh (-0.75%)
NWQ Managers 422,546 sh (-0.78%)
Ken Fisher 269,075 sh (-2.02%)
Pioneer Investments 16,205 sh (-2.61%)
Paul Tudor Jones 3,335 sh (-7.36%)
Chuck Royce 192,930 sh (-10.65%)
Joel Greenblatt 67,705 sh (-25.83%)
» More
Q2 2016

BIO Guru Trades in Q2 2016

Steven Cohen 38,800 sh (New)
Mariko Gordon 20,392 sh (New)
NWQ Managers 503,466 sh (+19.15%)
Ken Fisher 281,583 sh (+4.65%)
Pioneer Investments 16,205 sh (unchged)
Joel Greenblatt Sold Out
Paul Tudor Jones Sold Out
John Rogers 980,851 sh (-2.35%)
Mario Gabelli 63,200 sh (-4.96%)
Chuck Royce 178,630 sh (-7.41%)
Jim Simons 47,100 sh (-67.49%)
» More
Q3 2016

BIO Guru Trades in Q3 2016

Paul Tudor Jones 4,484 sh (New)
Ken Fisher 290,416 sh (+3.14%)
Steven Cohen 38,300 sh (-1.29%)
John Rogers 958,046 sh (-2.33%)
Mario Gabelli 61,112 sh (-3.30%)
Mariko Gordon 19,217 sh (-5.76%)
NWQ Managers 470,577 sh (-6.53%)
Jim Simons 43,000 sh (-8.70%)
Chuck Royce 150,030 sh (-16.01%)
Pioneer Investments 5,009 sh (-69.09%)
» More
Q4 2016

BIO Guru Trades in Q4 2016

George Soros 2,200 sh (New)
Paul Tudor Jones 59,100 sh (+1218.02%)
Mariko Gordon 20,348 sh (+5.89%)
Pioneer Investments Sold Out
Chuck Royce 148,630 sh (-0.93%)
Ken Fisher 283,625 sh (-2.34%)
Mario Gabelli 59,062 sh (-3.35%)
John Rogers 886,827 sh (-7.43%)
NWQ Managers 406,157 sh (-13.69%)
Jim Simons 31,200 sh (-27.44%)
Steven Cohen 12,700 sh (-66.84%)
» More
» Details

Insider Trades

Latest Guru Trades with BIO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 334516    SIC: 3826
Compare:OTCPK:BMXMF, NYSE:PKI, NAS:QGEN, OTCPK:SUVPF, NAS:DXCM, NAS:ICLR, NYSE:CRL, NAS:CPHD, NAS:PRAH, NAS:BRKR, NAS:VWR, OTCPK:CZMWY, NYSE:ALR, NAS:PRXL, NAS:NEOG, NAS:INCR, NAS:EXAS, NAS:MYGN, NAS:AXDX, NAS:FMI » details
Traded in other countries:BUWA.Germany,
Bio-Rad Laboratories Inc manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a products and systems used to separate complex chemical and biological materials.

Bio-Rad Laboratories Inc was founded in 1952 and incorporated in 1957. The Company manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. It operates in two industry segments designated as Life Science and Clinical Diagnostics. Life science is the study of the characteristics, behavior, and structure of living organisms and their component systems. Life Science segment is at the forefront of discovery, creating tools to answer complex biological questions. The Company is engaged in developing, manufacturing and marketing a range of more than 5,000 reagents, apparatus and laboratory instruments that serve a wide customer base. Many of its products are used in established research techniques, biopharmaceutical production processes and food testing regimes. These techniques are typically used to separate, purify and identify biological materials such as proteins, nucleic acids and bacteria within a laboratory or production setting. Its main life science customers include universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers and food testing laboratories. Clinical Diagnostics segment designs, manufactures, sells and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the diagnostics market. Its products currently address specific niches within the in vitro diagnostics (IVD) test market. It supplies more than 3,000 different products that cover more than 300 clinical diagnostic tests to the IVD test market. IVD tests are conducted outside the human body and are used to identify and measure substances in a patient's tissue, blood or urine. Its products consist of reagents, instruments and software, typically provided to its customers as an integrated package to allow them to generate reproducible test results. Its main clinical diagnostic customers include hospital laboratories, reference laboratories, transfusion laboratories and physician office laboratories. The Company owns numerous U.S. and international patents and patent licenses. Each of the Company's segments maintains a sales force to sell its products on a direct basis. Major competitors in the clinical diagnostic segment include Roche, Abbott Laboratories (Diagnostic Division), Siemens Medical Diagnostics Solutions (formerly Dade-Behring, Diagnostics Products Corporation, and Bayer Diagnostics), Beckman Coulter, Becton-Dickinson, bioMérieux, Johnson & Johnson (Ortho Clinical Diagnostics), Thermo Fisher, Tosoh, Immucor, Cepheid, and DiaSorin. The Company's operations are subject to federal, state, local and foreign environmental laws and regulations that govern such activities as transportation of goods, emissio

Ratios

vs
industry
vs
history
PE Ratio 210.96
BIO's PE Ratio is ranked lower than
97% of the 115 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.02 vs. BIO: 210.96 )
Ranked among companies with meaningful PE Ratio only.
BIO' s PE Ratio Range Over the Past 10 Years
Min: 13.66  Med: 22.83 Max: 210.96
Current: 210.96
13.66
210.96
Forward PE Ratio 57.14
BIO's Forward PE Ratio is ranked lower than
91% of the 46 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.83 vs. BIO: 57.14 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 210.96
BIO's PE Ratio without NRI is ranked lower than
96% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.50 vs. BIO: 210.96 )
Ranked among companies with meaningful PE Ratio without NRI only.
BIO' s PE Ratio without NRI Range Over the Past 10 Years
Min: 13.66  Med: 22.83 Max: 210.96
Current: 210.96
13.66
210.96
Price-to-Owner-Earnings 239.15
BIO's Price-to-Owner-Earnings is ranked lower than
95% of the 61 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 27.06 vs. BIO: 239.15 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
BIO' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 9.69  Med: 20.15 Max: 239.15
Current: 239.15
9.69
239.15
PB Ratio 2.29
BIO's PB Ratio is ranked higher than
74% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.55 vs. BIO: 2.29 )
Ranked among companies with meaningful PB Ratio only.
BIO' s PB Ratio Range Over the Past 10 Years
Min: 1.45  Med: 1.81 Max: 3.02
Current: 2.29
1.45
3.02
PS Ratio 2.87
BIO's PS Ratio is ranked higher than
53% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.06 vs. BIO: 2.87 )
Ranked among companies with meaningful PS Ratio only.
BIO' s PS Ratio Range Over the Past 10 Years
Min: 0.87  Med: 1.58 Max: 2.87
Current: 2.87
0.87
2.87
Price-to-Free-Cash-Flow 79.50
BIO's Price-to-Free-Cash-Flow is ranked lower than
85% of the 73 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.34 vs. BIO: 79.50 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
BIO' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 9.61  Med: 25.61 Max: 469.08
Current: 79.5
9.61
469.08
Price-to-Operating-Cash-Flow 27.44
BIO's Price-to-Operating-Cash-Flow is ranked lower than
69% of the 86 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.21 vs. BIO: 27.44 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
BIO' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 7.48  Med: 13.05 Max: 45.73
Current: 27.44
7.48
45.73
EV-to-EBIT 86.90
BIO's EV-to-EBIT is ranked lower than
95% of the 101 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.46 vs. BIO: 86.90 )
Ranked among companies with meaningful EV-to-EBIT only.
BIO' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.4  Med: 13.5 Max: 87.1
Current: 86.9
8.4
87.1
EV-to-EBITDA 26.73
BIO's EV-to-EBITDA is ranked lower than
73% of the 108 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 16.84 vs. BIO: 26.73 )
Ranked among companies with meaningful EV-to-EBITDA only.
BIO' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6  Med: 9.3 Max: 26.8
Current: 26.73
6
26.8
Shiller PE Ratio 45.32
BIO's Shiller PE Ratio is ranked lower than
60% of the 30 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 39.56 vs. BIO: 45.32 )
Ranked among companies with meaningful Shiller PE Ratio only.
BIO' s Shiller PE Ratio Range Over the Past 10 Years
Min: 19.63  Med: 27.84 Max: 45.34
Current: 45.32
19.63
45.34
Current Ratio 3.91
BIO's Current Ratio is ranked higher than
69% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. BIO: 3.91 )
Ranked among companies with meaningful Current Ratio only.
BIO' s Current Ratio Range Over the Past 10 Years
Min: 1.87  Med: 2.92 Max: 4.1
Current: 3.91
1.87
4.1
Quick Ratio 2.80
BIO's Quick Ratio is ranked higher than
63% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.17 vs. BIO: 2.80 )
Ranked among companies with meaningful Quick Ratio only.
BIO' s Quick Ratio Range Over the Past 10 Years
Min: 1.25  Med: 2.3 Max: 3.14
Current: 2.8
1.25
3.14
Days Inventory 207.71
BIO's Days Inventory is ranked lower than
91% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 77.88 vs. BIO: 207.71 )
Ranked among companies with meaningful Days Inventory only.
BIO' s Days Inventory Range Over the Past 10 Years
Min: 156.44  Med: 173.53 Max: 207.71
Current: 207.71
156.44
207.71
Days Sales Outstanding 65.71
BIO's Days Sales Outstanding is ranked lower than
56% of the 142 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 61.18 vs. BIO: 65.71 )
Ranked among companies with meaningful Days Sales Outstanding only.
BIO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 63.37  Med: 70.54 Max: 89.45
Current: 65.71
63.37
89.45
Days Payable 52.24
BIO's Days Payable is ranked lower than
53% of the 135 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 57.49 vs. BIO: 52.24 )
Ranked among companies with meaningful Days Payable only.
BIO' s Days Payable Range Over the Past 10 Years
Min: 43.27  Med: 52.25 Max: 56.81
Current: 52.24
43.27
56.81

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -0.90
BIO's 3-Year Average Share Buyback Ratio is ranked higher than
73% of the 132 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.80 vs. BIO: -0.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BIO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -1.3  Med: -1.1 Max: -0.2
Current: -0.9
-1.3
-0.2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 10.19
BIO's Price-to-Net-Current-Asset-Value is ranked lower than
57% of the 128 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.22 vs. BIO: 10.19 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
BIO' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 3.17  Med: 7.23 Max: 95.94
Current: 10.19
3.17
95.94
Price-to-Tangible-Book 3.04
BIO's Price-to-Tangible-Book is ranked higher than
71% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.72 vs. BIO: 3.04 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
BIO' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.34  Med: 2.88 Max: 6.43
Current: 3.04
1.34
6.43
Price-to-Intrinsic-Value-Projected-FCF 1.94
BIO's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
55% of the 76 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. BIO: 1.94 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
BIO' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.81  Med: 1.32 Max: 17.2
Current: 1.94
0.81
17.2
Price-to-Median-PS-Value 1.81
BIO's Price-to-Median-PS-Value is ranked lower than
87% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.03 vs. BIO: 1.81 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BIO' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.32  Med: 0.93 Max: 1.81
Current: 1.81
0.32
1.81
Price-to-Graham-Number 5.34
BIO's Price-to-Graham-Number is ranked lower than
74% of the 62 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.91 vs. BIO: 5.34 )
Ranked among companies with meaningful Price-to-Graham-Number only.
BIO' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.8  Med: 1.76 Max: 5.34
Current: 5.34
0.8
5.34
Earnings Yield (Greenblatt) % 1.15
BIO's Earnings Yield (Greenblatt) % is ranked higher than
57% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.78 vs. BIO: 1.15 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BIO' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.1  Med: 7.4 Max: 11.9
Current: 1.15
1.1
11.9
Forward Rate of Return (Yacktman) % -9.16
BIO's Forward Rate of Return (Yacktman) % is ranked lower than
88% of the 58 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.41 vs. BIO: -9.16 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
BIO' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -9.2  Med: 10.6 Max: 22.4
Current: -9.16
-9.2
22.4

More Statistics

Revenue (TTM) (Mil) $2,068
EPS (TTM) $ 0.95
Beta0.89
Short Percentage of Float3.54%
52-Week Range $131.78 - 209.50
Shares Outstanding (Mil)29.58

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 2,125 2,218 2,315
EPS ($) 3.50 4.29 5.24
EPS without NRI ($) 3.50 4.29 5.24
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for BIO

Headlines

Articles On GuruFocus.com
Mariko Gordon Invested in 5 Companies in 2nd Quarter Aug 21 2016 
Royce 100 Fund Shareholder Letter Sep 20 2015 
Widely Held Guru Stocks Near Historical Low P/B Ratios Aug 11 2014 
Guru Held Stocks Near Historical Low P/B Jul 22 2014 
Morning Coffee: Widely Held Guru Stocks Near Historical Low P/B Jun 02 2014 
Morning Coffee: Widely Held Guru Stocks Near Historical Low P/B May 27 2014 
Morning Coffee: Widely Held Guru Stocks Near Historical Low P/B May 19 2014 
Morning Coffee: Widely Held Guru Stocks Near Historic Low P/B May 12 2014 
Morning Coffee: Widely Held Guru Stocks Near Historical Low P/B Apr 23 2014 
Morning Coffee: Widely Held Guru Stocks Near Historical Low P/B Apr 14 2014 

More From Other Websites
BIO RAD LABORATORIES INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Mar 13 2017
Bio-Rad Initiates Long Term Financial Guidance; Commits to Defining Long Term Capital Allocation... Mar 13 2017
Bio-Rad Intends to Propose Three New Independent Directors Mar 13 2017
BIO RAD LABORATORIES INC Financials Mar 04 2017
BIO RAD LABORATORIES INC Files SEC form 10-K, Annual Report Mar 01 2017
Bio-Rad Laboratories, Inc. :BIO-US: Earnings Analysis: 2016 By the Numbers : February 27, 2017 Feb 27 2017
Bio-Rad Reports 4Q Loss, Flat Revenue Feb 27 2017
Bio-Rad Laboratories, Inc. :BIO-US: Earnings Analysis: Q4, 2016 By the Numbers : February 24, 2017 Feb 24 2017
Bio-Rad reports 4Q loss Feb 24 2017
Bio-Rad reports 4Q loss Feb 24 2017
Bio-Rad reports 4Q loss Feb 24 2017
Edited Transcript of BIO earnings conference call or presentation 23-Feb-17 10:00pm GMT Feb 23 2017
BIO RAD LABORATORIES INC Files SEC form 8-K, Results of Operations and Financial Condition,... Feb 23 2017
Bio-Rad Reports Fourth-Quarter and Full-Year 2016 Financial Results Feb 23 2017
Q4 2016 Bio Rad Laboratories Inc Earnings Release - After Market Close Feb 23 2017
New Strong Sell Stocks for February 22nd Feb 22 2017
MedTech Stocks' Earnings Due on Feb 23: TFX, SAUHF, BIO, PDCO Feb 22 2017
New Strong Sell Stocks for February 17th Feb 17 2017
Corruption Currents: Trump, Putin to Discuss Sanctions on Russia Jan 27 2017
Bio-Rad to Report Fourth-Quarter and Full-Year 2016 Financial Results Thursday, February 23, 2017 Jan 18 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)